First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease
The levodopa/carbidopa microtablets,2 5/1.25 mg (LC‐5, Flexilev®, Sensidose® AB, Sollentuna, Sweden), dispensed with the automatic dose dispenser4 MyFID™, were used in Sweden on licensed prescription from 2013. The treatment was approved in 2014 by the MPA in Sweden and recently approved (2016) by the EMA in 13 EU countries following the mutual recognition procedure. The dose dispenser is equipped with an alarm to facilitate treatment adherence, and a diary function, enabling patient self‐reporting of symptoms and disease overview.
The aim of this evaluation was to assess the initial experience of the treatment with LC‐5 and the dose dispenser with respect to efficacy and usability.